Moleculin Biotech - MBRX Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings or view top-rated stocks.

1 analysts have issued 1-year target prices for Moleculin Biotech's stock. Their MBRX share price forecasts range from $5.00 to $16.00. On average, they expect the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 746.8% from the stock's current price.
View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts.

Moleculin Biotech's stock was trading at $1.06 at the beginning of 2023. Since then, MBRX shares have increased by 17.0% and is now trading at $1.24.
View the best growth stocks for 2023 here.

Moleculin Biotech saw a decline in short interest in January. As of January 15th, there was short interest totaling 77,200 shares, a decline of 34.9% from the December 31st total of 118,600 shares. Based on an average daily volume of 101,300 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.3% of the shares of the company are short sold.
View Moleculin Biotech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our MBRX earnings forecast.

Moleculin Biotech, Inc. (NASDAQ:MBRX) announced its earnings results on Thursday, November, 10th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.03. During the same quarter last year, the company posted ($0.15) earnings per share.

Shares of Moleculin Biotech reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MBRX stock can currently be purchased for approximately $1.24.

Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $35.50 million. The company earns $-15,890,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com.